… Because nirmatrelvir/ritonavir is prescribed for the treatment of mild to moderate COVID-19,
we postulated that the impact of COVID-19 related cytokine storm on enzymes and …

… but excluded individuals with a history of prior COVID-19 or vaccination. The incidence of …
the nirmatrelvir/ritonavir EUA. This is in line with higher rates of hospitalization for COVID-19 in …

… the effectiveness of sotrovimab, molnupiravir, and nirmatrelvir-ritonavir in preventing hospital
admission and death in higher-risk patients (Fig. 1) with COVID-19 in Wales, UK, during the …

Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19 The nirmatrelvir-ritonavir (Paxlovid®)
is a treatment against Covid-19 available in pharmacies since February 4, 2022. …

… The median time to sustained alleviation of all targeted signs and symptoms of Covid-19
was 12 days in the nirmatrelvir–ritonavir group and 13 days in the placebo group (P=0.60). Five …

… Nirmatrelvir inhibits a protease enzyme produced by SARS-CoV-2 that is necessary for viral
replication. Low-dose ritonavir is combined with nirmatrelvir as a … Ritonavir is an inhibitor of …

… Utilizing a multivariable Cox model with time-updated exposure to nirmatrelvir/ritonavir,
nirmatrelvir/ritonavir was associated with a reduction in the hazard of COVID-19 hospitalization (…

… In this work, we compare efficacy of molnupiravir and nirmatrelvir/ritonavir in the Roborovski
dwarf hamster model of severe COVID-19-like viral pneumonia and the ferret transmission …

… of nirmatrelvir plus ritonavir (NMV-r) on post-acute COVID-19 … We identified nonhospitalized
adult patients with COVID-19 … and a composite of post-COVID-19 symptoms according to the …

… of timely COVID-19 treatment using nirmatrelvir/ritonavir … symptom onset, nirmatrelvir/ritonavir
significantly reduced the … investigated whether initiating nirmatrelvir/ritonavir earlier or …